Biotech investors should keep a close eye on the progress in this huge potential market.
The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.
Doug Kass shares his thoughts on Apple, Allergan and Western Digital.
Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.